Lee Financial’s NovoCure NVCR Stock Holding History

Lee Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15	Closed	-$3K	–	720
2021 Q2	$3K	Buy	+15	New	+$2.92K	﹤0.01%	519

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lee Financial's NVCR Position: Q3 2021 in Review

Lee Financial sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 15 shares — an estimated $3K sold.

Lee Financial first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

Lee Financial reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
Lee Financial sold 15 NovoCure shares in Q3 2021, an estimated $3K.
Lee Financial first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
Lee Financial's NovoCure position peaked at $3K in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Lee Financial's 13F filing for Q3 2021, filed 12 Nov 2021.